In this webinar, Dr. Lei Shi introduces Biointron's antibody discovery platform and applications.
Increasingly, antibody drug development requires quick and holistic assessment from the discovery stage with a powerful platform, which demands experienced scientists make smart and strategic choices. We will discuss how Biointron‘s unique single B cell sorting-based antibody screening can help identify a population of diverse and functional hits with a shortened timeline. Integrated with our high-throughput expression, validation and developability assay platforms, the path from hits to candidate can be more faster and more efficient with data beyond binding alone.
Presenters
Senior Vice President
Biointron
Lei Shi, PhD is Senior Vice President of Biointron. He has more than 20 years of experience in antibody discovery.
Production Partner
Biointron
Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 3,000 biotech and pharma companies worldwide.
Additional Content From Biointron
From Single Domain to Single B: Leveraging Biointron’s Expertise for Antibody Discovery Success
In this webinar, we present Biointron’s proven expertise in two discovery approaches: VHH Phage Display for single-domain antibody generation and AbDrop® Single B Cell Screening for rapid antibody discovery.
Introduction to Bispecific Antibodies and Their Production
In this webinar, Dr. Brady Wu discusses bispecific antibody drugs and their production.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
Related Content
From Clinical Data to Actionable Assets for Pharmaceutical R&D
In this webinar, learn to transform raw clinical and biobanking data into research-ready assets to accelerate pharmaceutical R&D.
Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping
Join us to learn how in-depth in vivo phenotyping using patient-relevant models can improve preclinical decision-making.